The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 14, 2019
Filed:
May. 15, 2017
Applicant:
Anygen Co., Ltd., Gwangju, KR;
Inventors:
Jae il Kim, Gwangju, KR;
Seon-Myung Kim, Gwangju, KR;
San Ho Kim, Gwangju, KR;
Moon Young Park, Gwangju, KR;
Assignee:
ANYGEN CO., LTD., Gwangju, KR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/404 (2006.01); A61K 31/4155 (2006.01); A61K 45/06 (2006.01); C07D 209/38 (2006.01); C07D 403/04 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/404 (2013.01); A61K 31/4155 (2013.01); A61K 45/06 (2013.01); C07D 209/38 (2013.01); C07D 403/04 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract
A breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3′-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed.